Skip to main content
Fig. 9 | BMC Biotechnology

Fig. 9

From: The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in rats

Fig. 9

NicA2 effects on nicotine or sucrose self-administration. Mean (± SD) nicotine self-administration (infusion rate) and sucrose-maintained responding (pellet delivery rate) following pretreatment with PBS vehicle (V) and NicA2 over four consecutive test sessions, expressed as a percentage of baseline. A total of 8 rats responding for nicotine were treated with NicA2. Of these, 5 showed a decrease in NSA (Panel a; Decreasers) and 3 showed an increase in NSA (Panel b; Compensators). Two of these “compensators” were allowed to re-establish baseline NSA and were then treated with 70 mg/kg NicA2 (Panel b). Five additional rats responded for sucrose and received NicA2 (Panel a). The dotted horizontal line represents baseline. The dashed horizontal line represents the 50% reduction criterion for extinction

Back to article page

BMC Biotechnology

ISSN: 1472-6750

Contact us